Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.verified

ATNM

Price:

$1.76

Market Cap:

$54.83M

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple...[Read more]

Industry

Biotechnology

IPO Date

2012-12-27

Stock Exchange

AMEX

Ticker

ATNM

The PE Ratio as of November 2024 (TTM) for Actinium Pharmaceuticals, Inc. (ATNM) is -1.17

According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.17. This represents a change of -74.62% compared to the average of -4.61 of the last 4 quarters.

Actinium Pharmaceuticals, Inc. (ATNM) Historical PE Ratio (quarterly & annually)

How has ATNM PE Ratio performed in the past?

The mean historical PE Ratio of Actinium Pharmaceuticals, Inc. over the last ten years is -3.92. The current -1.17 PE Ratio has changed 2.89% with respect to the historical average. Over the past ten years (40 quarters), ATNM's PE Ratio was at its highest in in the March 2018 quarter at -1.28. The PE Ratio was at its lowest in in the December 2014 quarter at -9.02.

Quarterly (TTM)
Annual

Average

-3.92

Median

-3.53

Minimum

-8.05

Maximum

-1.50

Actinium Pharmaceuticals, Inc. (ATNM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 187.15%

Maximum Annual PE Ratio = -1.50

Minimum Annual Increase = -70.26%

Minimum Annual PE Ratio = -8.05

Quarterly (TTM)
Annual
YearPE RatioChange
2023-2.77-65.62%
2022-8.0560.14%
2021-5.0317.08%
2020-4.29187.15%
2019-1.50-13.79%
2018-1.734.20%
2017-1.67-4.50%
2016-1.74-70.26%
2015-5.86-10.21%
2014-6.53-47.52%

Actinium Pharmaceuticals, Inc. (ATNM) Average PE Ratio

How has ATNM PE Ratio performed in the past?

The current PE Ratio of Actinium Pharmaceuticals, Inc. (ATNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.28

5-year avg

-4.33

10-year avg

-3.92

Actinium Pharmaceuticals, Inc. (ATNM) PE Ratio vs. Peers

How is ATNM’s PE Ratio compared to its peers?

Actinium Pharmaceuticals, Inc.’s PE Ratio is greater than MiNK Therapeutics, Inc. (-1.58), less than Affimed N.V. (-0.58), greater than ImmunoGen, Inc. (-122.93), greater than Adaptimmune Therapeutics plc (-2.90), greater than Sangamo Therapeutics, Inc. (-1.42), greater than Rigel Pharmaceuticals, Inc. (-17.35), less than Fortress Biotech, Inc. (-0.70), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), greater than CTI BioPharma Corp. (-30.90), greater than Ocuphire Pharma, Inc. (-2.14), greater than Annovis Bio, Inc. (-2.29), greater than Cassava Sciences, Inc. (-77.66), greater than Axsome Therapeutics, Inc. (-13.45), less than Seres Therapeutics, Inc. (-0.75), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), less than Eyenovia, Inc. (-0.74), less than Cognition Therapeutics, Inc. (-0.61), less than TransCode Therapeutics, Inc. (-0.20), less than Kodiak Sciences Inc. (-1.04), less than Exelixis, Inc. (20.98), less than TG Therapeutics, Inc. (36.85), greater than Viking Therapeutics, Inc. (-70.63), greater than Madrigal Pharmaceuticals, Inc. (-13.89), less than BioXcel Therapeutics, Inc. (-0.24),

Build a custom stock screener for Actinium Pharmaceuticals, Inc. (ATNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Actinium Pharmaceuticals, Inc. (ATNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Actinium Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Actinium Pharmaceuticals, Inc. (ATNM)?

What is the highest PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?

What is the 3-year average PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?

What is the 5-year average PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?

How does the current PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?